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Title: Focussing on the foot in psoriatic arthritis: pathology and 
management options 
 










Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis characterised by a 
range of musculoskeletal conditions including enthesitis, dactylitis and synovitis as well as 
skin and nail manifestations. The foot is a complex mixture of tissues all of which can be 




In this under researched area articles were taken from the authors publications and known 
other authors. This review will discuss how PsA affects the foot and ankle with particular 
focus on synovitis, tenosynovitis, enthesitis, dactylitis, bone erosion and psoriatic skin and 
nail disease. The use of imaging is discussed. Conventional radiography is consistently used, 
however magnetic resonance imaging and ultrasound should be used routinely to diagnose, 
assess and monitor the disease appropriately. The complex nature of PsA in the foot and 
ankle should be considered when managing the condition and treatment should be 




The foot and ankle remains a neglected area in PsA. Problems with the foot and ankle 
should be prioritised as they can significantly impact on patients’ quality of life. Focussing 






Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease which forms part of the 
spondyloarthropathy family. In addition to gastrointestinal, ocular and cardiovascular involvement, 
patients can present with several musculoskeletal manifestations including polyarthritis, 
oligoarthritis, sacroiliitis, enthesitis, dactylitis, and tenosynovitis [1, 2]. Peripheral joint and soft 
tissue involvement in the foot can manifest around the forefoot, midfoot and hindfoot right from 
the onset of disease with forefoot deformity affecting over 90% of patients with established disease 
[3, 4].  
 
2. Clinical Features 
2.1 Skin and Nail Disease 
Generally patients present with psoriasis before developing PsA (60-80%) [5] and around 30% of 
patients with psoriasis will go on to develop PsA [6, 7]. Psoriatic plaques can often be found on the 
dorsum of the foot (Figure 1) but patients can also present with palmoplantar pustulosis, which is 
considerably rarer (3-4%) [4, 8] . The main features of palmoplantar pustulosis include 
intraepidermal pustules, erythema, scaling and fissuring skin on the palms and/or soles of the feet 
which can greatly impact quality of life. Management usually consists of topical treatment as a first-
line approach (corticosteroids, salicylic acid, etc.) but often requires systemic treatment (oral 
retinoids, methotrexate, etc.)[8].  
 
The incidence of nail disease in PsA is reported to be around 65% [1, 9] yet it is often overlooked 
despite patients reporting that it can impact activities of daily living and cause pain and discomfort 
[10]. Researchers propose that nail changes in PsA may arise due to Koebner phenomenon [11, 12] 
and research by Tan et al, revealed the fascia of the nail root has a tenuous connection to the 




Nail disease in PsA (Figure 1) can be divided into changes arising from the nail matrix and changes 
involving the nail bed. Typical nail matrix disease includes leukonychia (white discoloration), 
onychorrhexis (nail ridging), nail pitting and blood spots on the lunula whereas nail bed disease can 
present as onycholysis (separation of the nail from the nail bed) (Figure 2), splinter haemorrhages 
and subungal hyperkeratosis [9]. There are a number of scoring systems to assess the extent of nail 
disease including the Nail Psoriasis Severity Index (NAPSI) and the Psoriasis Nail Severity Score 
(PNSS) [14, 15] but it is often difficult to differentiate from bacterial and fungal infections which can 




Enthesitis is a prominent feature of PsA presenting as inflammation at the insertion sites of tendons, 
ligaments, fascia and joint capsules to bone [16], and was initially noted as a possible manifestation 
of the disease that could distinguish spondyloarthropathies from rheumatoid arthritis (RA) [17]. It is 
present in 28%-35% [18-20] of patients who have PsA and may be the initial presenting clinical 
feature of the disease.  The presence of enthesitis may be an adverse prognostic factor: one study 
found an association with elevated disease activity and self-reported pain and fatigue, poorer 
functional status and greater overall burden of disease [21].  
 
The insertion of the Achilles tendon at the heel is the most prevalent site affected (3, 6) (Figure 3) 
however enthesitis can also typically be detected in the foot at the insertion of the plantar fascia at 
the calcaneus, tibialis posterior at the navicular tuberosity and peroneus brevis tendon at the base of 
the fifth metatarsal. A clinical enthesitis index, specific to PsA, has been developed which examines 
tenderness at six points of the body: bilateral lateral epicondyle of the humerous, medial condyle of 
the femur and the Achilles tendons at the posterior prominence of the calcaneus [22] however the 
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location and presentation of enthesitis in the foot can make it challenging to differentiate clinically 
from synovitis, bursitis and other inflammatory joint manifestations [23] (Figure 4). Enthesitis was 
typically under-diagnosed in patients with PsA however the routine use of ultrasound and MRI for 
assessing and monitoring the disease has increased the detection of enthesitis and enables more 
detailed investigation. Both modalities provide different, valuable information: MR imaging allows 
assessment of soft-tissue, entheseal and bone oedema, bone erosion and enthesophyte formation 
while ultrasound assesses vascularisation (power Doppler ultrasound (PDUS)), echogenicity, fluid, 
ligament abnormalities and tendon thickening [24]. The severity of enthesitis detected by ultrasound 
is a potential marker for peripheral and axial radiographic joint damage [25] however a recent study 
found no correlation at the insertion of the Achilles tendon [26].  
 
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend 
the use of NSAIDs as the first-line treatment for targeting enthesitis then TNF inhibitors and/or IL-
12/23 inhibitors as there is no empirical evidence to suggest traditional DMARDs have any effect 
[27]. In addition, the use of IL-17 inhibitors have demonstrated benefits in treating enthesitis as well 
as better outcomes overall, particularly for skin disease [28]. Due to the high risk of tendon rupture, 
local corticosteroid injections should be used with extreme caution at load-bearing entheses - 
particularly at the Achilles tendon insertion - however it is possible to inject into the retrocalcaneal 
bursae to achieve some therapeutic effect [4, 27]. Podiatry and physiotherapy are often prescribed 
despite the lack of evidence, but the benefit shown in managing foot disease in RA and clinical 
experience suggests they may be able to provide relief through the provision of orthoses, stretching 







Dactylitis, also known as ‘sausage’ digit, is a hallmark clinical feature of PsA and other 
spondyloarthropathies presenting as an acutely painful, uniformly swollen digit. Of the 39-48% of 
patients with PsA who have dactylitis, 75% of these cases occur in the foot [29, 30]. Dactylitis can be 
an early indicator of PsA and forms part of the classification criteria for diagnosing PsA [31, 32]. 
Similarly to enthesitis, the presence of dactylitis is a potential adverse prognostic factor and is 
associated with elevated disease activity, poorer functional status and greater disease burden 
compared to those without dactylitis [21]. Dactylitis may be a marker for arthritis mutilans in which 
typical changes such as erosion of the terminal phalangeal tufts, juxta-articular and entheseal new 
bone formation, periostitis, and severe osteolysis are seen on plain radiography [33]. MRI may show 
inflammation in several tissues, including tenosynovitis, synovitis, enthesitis and bone oedema. The 
European League Against Rheumatism (EULAR) and GRAPPA recognise the significance of dactylitis 
and recommend the use of biologics for patients with active dactylitis (and/or enthesitis) who do not 
respond to NSAIDs or local corticosteroid injections [27, 34]. 
 
Imaging studies have shown dactylitis to be a complex disorder with a wide range of features 
including synovitis, tenosynovitis, enthesitis, capsulitis, soft tissue thickening, bone oedema, and nail 
abnormalities (plate and bed) in the acute stage. However when the acute inflammation subsides, 
MRI scans still show abnormalities in the affected digit [35]. Current evidence suggests active foot 
disease persists in many patients despite recent treatment advances and the concept of “tight 
control” of disease [36]. Only a small proportion (20%) of those with moderate to high levels of foot 
related impairment and disability will receive foot care [3] with no evidence to support the use of 




Dactylitis most commonly occurs in the fourth toe and index finger and trauma has been 
hypothesised as a potential trigger for PsA. High levels of stress at entheses are suggested to be a 
biomechanical trigger to enthesitis and other manifestations of this disease [37, 38]. The load 
bearing function of toes during activities of daily living supports the mechanical pathogenesis 
hypothesis of toe dactylitis.  A previous study, undertaken by Wilkins et al, found no significant 
evidence linking plantar forefoot pressures (a measure of vertical stress) and the prevalence of toe 
dactylitis suggesting that examining plantar pressure alone provides limited understanding of toe 
dactylitis [39]. Knowledge of plantar shear stress distribution (a measure of stress in 
anterior/posterior, medial/lateral and vertical directions) could provide a greater insight into 
pathological foot function which is a potential trigger for toe dactylitis. To our knowledge, the only 
related study examining shear stress in inflammatory arthritis patients demonstrated increased 
plantar shear stresses and resulting pain [40].  
 
2.4 Synovitis and Tenosynovitis 
Synovitis is commonly found in the distal and proximal interphalangeal joints of the foot and other 
peripheral joints and is also present in around 14% of patients with PsA at the metatarsophalangeal 
(MTP) joints [41]. The synovium is a primary site of inflammation in PsA and can be characterised by 
a thinner synovial lining than patients with RA, increased vascularity in both synovium and psoriatic 
plaques and an overabundance of proinflammatory cytokines [42]. Due to the complexity and 
proximity of midfoot and forefoot pathology in PsA, it can be incredibly difficult to diagnose and 
assess synovitis clinically without the use of imaging.  
 
Unlike RA, patients with PsA can have residual synovial inflammation detectable by ultrasound even 
when they are in clinical remission [43] and recent research has found PDUS-detected synovitis 
7 
 
during remission is in fact a strong predictor of short-term flare [44]. Interestingly, subclinical 
synovitis is detected in around 30% of patients using PDUS at the MTP joints [45].  
 
Tenosynovitis, namely exudative and proliferative tenosynovitis, is commonly found in the foot and 
ankle in patients with PsA. Tenosynovitis also occurs in the dactylitic toe, primarily affecting the 
flexor tendons, which can be detected using MRI and ultrasound imaging [46]. Common areas for 
tenosynovitis include the tibialis posterior, common peroneal sheath and the long flexor tendons of 
flexor digitorum longus (Figure 4) and flexor hallucis longus at the ankle.  
 
Even in tendons which are not encased within a synovial sheath e.g. Achilles tendon, ultrasound can 
still detect inflammatory changes such as tendon thickening, intratendineous power Doppler signal 
and hypoechogenicity as a result of tendon oedema [47].  
 
2.5 Onychopachydermoperiostitis 
Psoriatic onychopachydermoperiostitis (POPP) syndrome is a clinical variant of psoriatic arthritis 
originally described by Fournie et al in 1989 [48]. Typically both hallux are involved in the presence 
of skin psoriasis, however it can occur in other digits, with associated  nail changes, painful swelling 
of the soft tissue close to the distal phalanx as well as specific radiologic changes such as periosteal 
reaction and bone erosions of the distal phalanges. However, distal interphalangeal joint 
involvement is characteristically absent. 
 
2.6 Juvenile psoriatic arthritis 
The diagnosis of juvenile PsA is defined by having two of the following: dactylitis, nail 
pitting/onycholysis, and/or psoriasis in a first-degree relative. The ankle and small joints of the 
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forefoot are often affected, including the painful presentation of dactylitis resulting in reduced 
physical function [49, 50]. Typical psoriatic skin and nail lesions are more subtle and less common in 
the juvenile PsA compared with that seen in adults. 
 
3. Imaging 
3.1 Conventional Radiography 
Conventional radiography (x-rays) is still routinely used to detect and monitor joint erosions, 
narrowing of the joint space and assess the density of subchondral bone [51]. Research has shown 
that within two years of developing PsA, around 32% of patients will present with radiographic joint 
erosions in the hands and feet despite clinical advances [52]. Overall factors predicting progression 
of radiological damage come from prospective cohort studies. In Toronto, the factors predicting 
progression were: erosions at presentation, higher baseline inflammation, and number of swollen 
and damaged joints [53].  However the predictors for radiological damage in the foot and ankle have 
not been determined.  
When imaging the foot and ankle it is often useful to take a weight-bearing x-ray as this is a more 
accurate representation of the foot structure and may also have greater relevance as the patient 
may be asymptomatic when non weight-bearing [4]. Conventional radiography does however have 
limitations: it is ineffective for assessing soft-tissues such as enthesitis, synovitis, tenosynovitis, 
tendinitis, bursitis and intraarticular effusions, all common features of PsA which must be detected 
and monitored throughout the disease course [54]. Other imaging modalities including 
ultrasonography and magnetic resonance imaging (MRI) are able to assess these changes and allow 
identification of inflammatory lesions soon after symptoms occur and before there is structural 
damage.  
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            3.2 MRI 
MRI is the most sensitive imaging modality for detecting inflammatory changes and is therefore the 
gold standard for assessing soft tissue and bone pathology in patients with PsA [55]. The structures 
and inflammatory processes you can visualise using MRI include: synovitis, bone erosions, bone 
oedema, enthesitis and dactylitis. However the disadvantages of using MRI over ultrasound imaging 
or conventional radiography include: high cost, limited clinical availability, few clinicians are able to 
interpret foot images and you may need to use an intravenous contrast agent if you aim to assess 
the soft tissues and bone simultaneously [4].  
 
         3.3 Ultrasound 
The complex nature of anatomical structures and proximity of soft tissues, tendons, ligaments and 
bones in the foot and ankle can make it difficult to obtain information from standard imaging 
modalities and differentiate clinically relevant pathology.  However, ultrasound is a practical imaging 
tool that allows the clinician to identify and assess a number of PsA pathologies. Ultrasound imaging 
of PsA patients typically involves grey scale/B mode assessment to assess structural change and 
PDUS to detect inflammation through measuring vascularity [55]. There are a number of structural 
changes detectable by grey scale/B mode ultrasound in the foot and ankle including bone erosions, 
enthesitis, synovitis, tendonitis and bursitis which would be difficult to distinguish clinically. In 
addition, PDUS is a useful tool for determining whether there is active inflammation or residual 
degenerative changes [56]. PDUS can detect changes in vascularity in soft tissues such as the 






When managing the foot in PsA the aim is for a zero-tolerance approach to active disease through 
pharmacological and non-pharmacological interventions and treatments. The evidence for managing 
foot and ankle disease in RA has shown there is a lack of basic foot health services for these patients 
and their foot health needs are not being met [58-61]. Despite the fact there is no evidence on the 
efficacy of podiatry involvement in the management of patients with PsA, it is well recognised that 
regular podiatry input is essential for holistic management of these patients.   
 
Only 20% of patients with PsA currently receive foot care despite over 60% self-reporting pain and 
moderate to severe levels of impairment and disability [3].  Research into RA has shown foot 
problems have a significant impact on patients’ quality of life by restricting mobility and the ability to 
work and socialise [61]. With similar manifestations, and the addition of enthesitis, dactylitis, 
psoriatic skin/nail disease and further pathology, it is fair to extend this observation to patients with 
PsA. 
 
Foot problems can be divided into primary i.e. they arise as a manifestation of PsA (synovitis, 
tenosynovitis, dactylitis etc.) or secondary i.e. loss of hand dexterity and function and/or axial 
involvement which can make it impossible for patients to carry out basic foot care, tie laces or fasten 
appropriate footwear. Redmond et al. advocate five areas of foot health provision for patients with 
rheumatic conditions including: education and self-management advice, provision of orthoses and 
footwear, general e.g. nail care, corn enucleation and callus reduction, the management of the high 




The feet should be assessed regularly by members of the rheumatology multidisciplinary teams and 
should be incorporated as part of the overall joint/skin assessment. Helliwell et al. published a ‘Look, 
Feel, Move’ model encouraging clinicians to carry out a simple, quick foot and ankle assessment: 
looking for changes in foot posture, swelling, and skin and nails changes then palpating joint margins 
and soft tissue structures and finally moving the ankle, subtalar, midfoot, MTP and interphalangeal 
joints to assess the range of motion and detect structural changes [62].  
 
Forefoot deformity such as hallux abducto valgus, often in conjunction with changes to foot posture, 
can result in difficulty finding suitable footwear particularly when, as previously mentioned, the 
patient is unable to manage due to hand and/or axial involvement. Patients should be encouraged to 
wear a wide-fitting shoe with more depth to accommodate the structural deformity and laces or a 
fastening to secure the shoe to the foot. Foot and ankle problems often result in a prolonged 
compensative gait typically leading to weakened muscles e.g. posterior calf muscles, and require 
muscle strengthening exercises specific to the muscle group affected. Although there is no evidence 
to support the benefit of using mechanical therapies in PsA, it is reasonable to assume that orthoses 
designed to attenuate mechanical stresses and used in patients with RA [63] would be beneficial in 
joints and soft tissues that are acutely inflamed or in those where disease remains locally persistent.  
The use of corrective functional foot orthoses, particularly in early disease to relieve pain and reduce 
mechanically driven inflammation by correcting the foot position, providing joint stabilisation, 
resting key anatomical structures and resisting the deforming forces will likely prevent the 
development of deformity.  Foot orthoses can also be used to redistribute high pressure areas and 
offload painful tendons and/or soft tissue structures. 
 
The management of PsA nail disease depends on the severity, duration of symptoms and how much 
it impacts the patients’ quality of life. When psoriatic nail disease is present, podiatrists can reduce 
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the thickness of onychauxic (thickened) nails to prevent onychocryptosis and subsequent infection - 
a serious consideration for immunosuppressed patients - and advise on safe topical treatments if 
there is a suspected infection.  When nail disease is widespread and significantly impacting the 
patient’s quality of life, or presents along with significant skin and/or joint disease, then systemic 
therapy is justified with strong evidence supporting the efficacy of TNF and IL-12/23 inhibitors [27].   
 
Despite the lack of research around the peripheral vascular supply of patients with PsA, it is 
important to assess the vascular supply to the lower limb as we know PsA is actually equivalent to 
RA and diabetes mellitus in terms of general cardiovascular risk [64]. Clinically this can be assessed 
by looking for skin colour changes, presence of hair and potential tissue breakdown/ulceration.  It is 
important to check the vascular supply to the foot by palpating the dorsalis pedis pulse as it runs 
over the dorsal prominence of the navicular bone and the posterior tibial pulse as it runs behind the 
medial malleolus. If they are not palpable a hand-held vascular Doppler should be used to locate 
these pulses and assess the strength of the blood flow to the peripheries.  
 
Local corticosteroid injections are advocated for chronic foot disease in PsA patients, despite a lack 
of evidence, to relieve symptoms and target areas of persistent inflammation. Ultrasound guided 
injections have been shown to improve the accuracy of intra-articular injections and may be more 
beneficial for the smaller joints of the feet and when there is significant structural abnormality 
present [65, 66].  
 
Surgery should be considered if pharmacological and conservative approaches are not effective, 
although the evidence to support surgical strategies is lacking in this group of patients. Guidelines 
typically recommend that patients are referred for a surgical opinion at an appropriate time, 
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although identifying when a patient should be referred for foot surgery is yet to be determined. 
Surgical synovectomy and radioactive synovectomy are seldom undertaken nowadays, possibly 
because of more effective systemic therapies for this disease. 
 
5. Conclusion 
Management of the foot in PsA should not be over-looked by clinicians as foot and ankle problems 
can have a significant impact on patients’ quality of life and foot focussed interventions can 






6. Expert Commentary 
Unfortunately there is no high quality evidence to support the management of foot problems in 
people with psoriatic arthritis. It has been proposed that the key to effective management of foot 
problems in people with rheumatoid arthritis is through staged and targeted interventions in early 
disease with the ultimate aim of zero tolerance of active disease in the foot; we advocate this 
approach to managing foot disease in people with psoriatic arthritis.  Strategies should combine 
pharmacological anti-inflammatory agents, including intraarticular and soft tissue steroid injections 
with physical therapies to prevent and reduce mechanical articular and peri-articular stresses.  In 
practice, however, there is evidence to suggest active foot disease persists in many patients despite 
recent treatment advances and the concept of “tight control” of disease.  Our future research needs 
to be directed at gaining a better understanding of the pathogenesis of foot disease in this group of 
patients to enable us to identify effective management strategies, aimed at preventing long term 
damage. 
A previous study, undertaken by our team in Leeds, found no significant evidence linking plantar 
forefoot pressures (a measure of vertical stress) and the prevalence of toe dactylitis, suggesting that 
examining plantar pressure alone provides limited understanding of toe dactylitis. Exploring other 
biomechanical reasons will provide a greater insight into pathological foot function which may act as 
a potential stress trigger for toe dactylitis and help us understand why it most commonly occurs in 
the fourth toe. We can then direct our further research to identifying appropriate interventions to 
reduce the impact of dactylitis. 
It is widely accepted that high levels of stress at entheses are suggested to be a biomechanical 
trigger to enthesitis and other manifestations of this disease; pharmacological therapies such as local 
steroid injections and systemic disease modifying drugs are used to treat the inflammation.  
However, we must also address the clinical question ‘do mechanical therapies work for enthesitis?’ 
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And should they be combined with pharmacological therapies such as local steroid injections to 
provide the most effective treatment?  
Skin and nail disease have both physical and psychosocial impacts on the person involved, which 
extends to include the foot.  Clinically we experience patients finding it difficult to wear a fully 
enclosed shoe due to pressure/rubbing on the skin and often discomfort from thickened nails.  
Therefore it is important that we understand what influence skin and nail disease has on the 
patient’s ability to wear orthoses and footwear, required to manage the biomechanical aspects of 
the disease. This leads to a further question; should we be treating the skin (and nails) aggressively 
for this reason?  
A research strategy aimed at understanding both the biomechanical and inflammatory mechanisms 
of foot disease in people with psoriatic arthritis provides the opportunity to address foot 
impairments and resulting disability and develop a personalised targeted approach to treatment.   
 
7. Five-year review 
This review has given us the opportunity to highlight the impact of foot disease, the potential 
mechanisms that cause the resulting impairment and disability and propose targeted treatment 
strategies.  We speculate that in five years our understanding of the manifestations of how the 
disease process affects the feet will have improved so that we can stratify patients to ensure that we 
target those who are a risk of developing deformity and disability.  This approach will enable us to 
design studies to determine the clinical and cost effectiveness of treatment strategies aimed at 






 Peripheral joint and soft tissue involvement in the foot can manifest around the forefoot, 
midfoot and hindfoot right from the onset of disease; forefoot deformity affects over 90% of 
patients with established disease.  
 The Achilles tendon insertion is the most prevalent site affected however enthesitis can also 
typically be detected in the foot at the insertion of the plantar fascia at the calcaneus, tibialis 
posterior at the navicular tuberosity and peroneus brevis tendon at the base of the fifth 
metatarsal. 
 Dactylitis can be an early indicator of PsA forming part of the classification criteria; of the 39-
48% of patients with PsA who have dactylitis, 75% of these cases occur in the foot and most 
commonly in the fourth toe. 
 The load bearing function of toes supports the mechanical pathogenesis hypothesis of toe 
dactylitis,   however recent evidence suggests that plantar forefoot pressures (a measure of 
vertical stress) are not linked to the prevalence of toe dactylitis. 
 Synovitis is commonly found in the distal and proximal interphalangeal joints of the foot as 
well at the metatarsophalangeal (MTP) joints. Clinical synovitis is present in 14% of patients 
with PsA at the MTP joints; interestingly, subclinical synovitis is detected in around 30% of 
patients using power Doppler ultrasound at the MTP joints. 
 Common areas for tenosynovitis include the tibialis posterior, common peroneal sheath and 
the long flexor tendons of flexor digitorum longus and flexor hallucis longus at the ankle. 
 Only 20% of patients with PsA currently receive foot care despite over 60% self-reporting 
pain and moderate to severe levels of impairment and disability.   
 The feet should be assessed regularly by members of the rheumatology multidisciplinary 
team and should be incorporated as part of the overall joint/skin assessment. 
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 Due to the high risk of tendon rupture, local corticosteroid injections should be used with 
extreme caution at load-bearing entheses i.e. the Achilles tendon insertion; injecting into the 
retrocalcaneal bursae will achieve some therapeutic effect. 
 Despite the lack of evidence, clinical experience suggests that foot symptoms are relieved 
through the provision of orthoses, stretching and footwear modification and advice. 
 Functional foot orthoses offer the potential to relieve pain, redistribute high pressure areas 
and offload painful tendons and/or soft tissue structures. 
 Surgery should be considered if pharmacological and conservative approaches are not 
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Figure Legends  
Figure 1: Plaque psoriasis on the dorsum of the foot and psoriatic nail disease. 
Figure 2: Psoriatic nail disease: onycholysis in the finger nails also seen in toe nails. 
Figure3:  Pronounced enthesitis at the Achilles tendon insertions 
Figure 4: Tenosynovitis of the tibialis posterior tendon and a large synovial cyst arising from 
the flexor digitorum longus tendon sheath of the right foot. 
 
